Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Simmons First National and Marriott International are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. If your holdings could benefit from diversification towards growth stocks, whether it be in reputable tech stocks or green small-caps, take a look at my list of stocks with a bright future ahead.
Simmons First National Corporation (NASDAQ:SFNC)
Simmons First National Corporation operates as the holding company for Simmons Bank that provides financial products and services to individuals and businesses. Started in 1903, and headed by CEO George Makris, the company size now stands at 2,640 people and with the market cap of USD $2.57B, it falls under the mid-cap group.
SFNC’s forecasted bottom line growth is an optimistic 40.36%, driven by the underlying 56.45% sales growth over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 10.10%. SFNC’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Could this stock be your next pick? Take a look at its other fundamentals here.
Marriott International, Inc. (NASDAQ:MAR)
Marriott International, Inc. operates, franchises, and licenses hotel, residential, and timeshare properties worldwide. Founded in 1927, and currently run by Arne Sorenson, the company employs 177,000 people and has a market cap of USD $47.14B, putting it in the large-cap stocks category.
MAR is expected to deliver a buoyant earnings growth over the next couple of years of 16.03%, bolstered by a significant revenue which is expected to more than double. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 82.43%. MAR’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Could this stock be your next pick? Take a look at its other fundamentals here.
Cancer Genetics, Inc. (NASDAQ:CGIX)
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Started in 1999, and now led by CEO John Roberts, the company employs 149 people and with the market cap of USD $40.02M, it falls under the small-cap stocks category.
Driven by the exceptional 61.51% sales growth over the next few years, CGIX is expected to deliver an excellent earnings growth of 66.99%. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. CGIX ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Considering CGIX as a potential investment? Other fundamental factors you should also consider can be found here.
For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.